Table A. SARS-CoV-2 Variants and Susceptibility to Anti-SARS-CoV-2 Monoclonal Antibodies

Last Updated: April 29, 2022

Table A. SARS-CoV-2 Variants and Susceptibility to Anti-SARS-CoV-2 Monoclonal Antibodies

Table A. SARS-CoV-2 Variants and Susceptibility to Anti-SARS-CoV-2 Monoclonal Antibodies
WHO Label	Pango Lineage	CDC Variant Class	Notable Mutations	BAM Plus ETE		CAS Plus IMD		BEB		SOT		TIX Plus CIL
WHO Label	Pango Lineage	CDC Variant Class	Notable Mutations	In Vitro Susceptibility^a	Anticipated Clinical Activity	In Vitro Susceptibility^a	Anticipated Clinical Activity	In Vitro Susceptibility^a	Anticipated Clinical Activity	In Vitro Susceptibility^a	Anticipated Clinical Activity	In Vitro Susceptibility^a	Anticipated Clinical Activity
Alpha	B.1.1.7	VBM	N501Y	No change	Active	No change	Active	No change	Active	No change	Active	No change	Active
Beta	B.1.351	VBM	K417N, E484K, N501Y	Marked reduction	Unlikely to be active	No change^b	Active	No change	Active	No change	Active	No change	Active
Gamma	P.1	VBM	K417T, E484K, N501Y	Marked reduction	Unlikely to be active	No change^b	Active	No change	Active	No change	Active	No change	Active
Delta	B.1.617.2, non-AY.1/ AY.2	VOC	L452R, T478K	No change	Active	No change	Active	No change	Active	No change	Active	No change	Active
Omicron	B.1.1.529/ BA.1	VOC	K417N, N440K, G446S, E484A, Q493R, N501Y	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active	No change	Active	No change	Active	Moderate reduction^c	Active^d
Omicron	B.1.1.529/ BA.1.1	VOC	R346K, K417N, N440K, G446S, E484A, Q493R, N501Y	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active	No change	Active	No change	Active	Moderate reduction^c	Active^d
Omicron	B.1.1.529/ BA.2	VOC	T376A, K417N, N440K, E484A, Q493R, N501Y	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active	No change	Active	Marked reduction	Unlikely to be active	No change	Active
^a Based on the fold reduction in susceptibility reported in the FDA EUAs.^8,11,15,16 ^b Marked change for CAS and no change for IMD. The combination of CAS plus IMD appears to retain activity against the variant. ^c Despite the moderately reduced in vitro susceptibility of TIX plus CIL, in vitro PK/PD modeling data suggest that the TIX 300 mg plus CIL 300 mg dose will retain activity against the Omicron VOC.¹¹ ^d The duration of protection against SARS-CoV-2 infection remains unclear. Key: BAM = bamlanivimab; BEB = bebtelovimab; CAS = casirivimab; CIL = cilgavimab; CDC = Centers for Disease Control and Prevention; ETE = etesevimab; EUA = Emergency Use Authorization; FDA = Food and Drug Administration; IMD = imdevimab; PK/PD = pharmacokinetic/pharmacodynamic; SOT = sotrovimab; TIX = tixagevimab; VBM = variant being monitored; VOC = variant of concern; WHO = World Health Organization